The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney

Uropathy Clinical Trial

Official title:

The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney: A Double Blind Randomized Placebo-controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04278495
• Other study ID #: LOSARTAN.OBST.UROPATHY
• Status: Completed
• Phase: N/A
• Start date: September 1, 2014
• Est. completion date: December 1, 2018

Study information

• Verified date: February 2020
• Source: Mansoura University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous experimental studies concluded that angiotensin receptor blockers can ameliorate the harmful inflammatory and histological changes after relief of obstruction. Nevertheless, these witnessed effects have not been yet translated into the clinical practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: December 1, 2018
• Est. primary completion date: December 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• anuric and oliguric patients

• calculuar ureteral obstruction

Exclusion Criteria:

• anomalous kidney

• bilateral obstructed kidney

• history of recent use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitors

• ASA score of >3

Related Conditions & MeSH terms

• Losartan Adverse Reaction
• Urologic Diseases
• Uropathy
• Uropathy Obstructive

Intervention

Drug:
• Cozaar (Losartan Potassium 25mg)
Cozaar (Losartan Potassium 25mg)
• Placebo
Placebo

Locations

Country	Name	City	State
Egypt	Urology and nephrology center	Mansoura	Outside U.S./Canada

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renographic glomerular filtration rate of the affected kidney.	assessed by radioisotope renography using 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) in ml/min	3 months
Secondary	Serum creatinine change	assessed by serum creatnine in mg/dl	3 months